Navigation Links
Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire/ -- aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor. An example of aTyr Pharma's broad intellectual property portfolio and the fifteenth filed patent related to aTyr Pharma's work in tRNA synthetases, this patent covers new extracellular activities for p43, a critical protein component of the multi-aminoacyl tRNA synthetase complex in humans. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

Jeff Watkins, CEO of aTyr Pharma, had this to say about the patent: "This patent covers discoveries Professor Kim has made for extracellular activity of the p43 component of the multi-sythetase complex. As part of aTyr Pharma's portfolio, this patent helps establish our dominant ownership and leadership in the resectin space. Capitalizing on this new area of biology, we are identifying and developing these naturally occurring resectins as candidate biotherapeutics for treating a wide variety of diseases."

Professor Kim, of Seoul National University in Korea, has had a long scientific relationship with Professor Paul Schimmel of The Scripps Research Institute and a co-founder of aTyr Pharma. According to Professor Schimmel, "Professor Kim's research has really helped build our understanding of how far-reaching the non-canonical functions are for naturally occurring resectins of tRNA synthetases and their associated proteins. This newly issued patent highlights the innovation surrounding the discovery and development of tRNA synthetase resectins as biotherapeutics." Professors Schimmel and Kim recently co-authored a scientific article in the Proceedings of the Natural Academy of Sciences (PNAS USA, 2008, vol. 105: 11043-11409) describing many of the newly emerging functions of tRNA synthetases and the relationships to human medicine.

Link to the PNAS review article: http://www.pnas.org/content/105/32/11043.full.pdf

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fifteenth Annual Pridelights Goes Green
2. Genova files patent for new prostate cancer treatment
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
4. TANCS Steam Vapor Granted U.S. Patent
5. Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
6. Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent
7. Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare
8. U.S. District Court Rules Against Lilly Regarding Gemzar Patent
9. Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
10. German District Court Rules in Smith & Nephews Favor in Patent Infringement Case
11. AlphaRx Receives China Patent on Its Drug Delivery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
Breaking Medicine Technology: